Health Law Informer

On February 23, the FDA announced a new approval pathway designed to support the development of drugs for ultra-rare diseases. Often, treatments for ultra-rare diseases have difficulty meeting the agency’s rigorous approval requirements. The FDA has issued a guidance document for the “Plausible Mechanism Framework,” which will allow drugmakers to bypass certain clinical trial requirements when advancing drugs treating ultra-rare conditions. Specifically, the framework will target products where randomized clinical trials are not feasible. Rather, the experience of individuals will inform the drug’s path to approval.  The therapies targeted will be those which are designed to correct or modify the underlying cause of a specific genetic, cellular, or molecular abnormality which causes disease. The framework may further apply to other tailored therapeutics, if they directly address the specific underlying cause of the disease.

The FDA recently shared information regarding its flexible approach to overseeing chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGT).  Due to the unique nature of the characteristics of CGT, regulatory flexibility must be adapted in a way that encourages increased innovation while still maintaining the integrity of safety and efficacy.

On July 10, 2025, citing a drive to increase transparency, the Food and Drug Administration (“FDA”) published more than 200 complete response letters (CRLs) previously issued to companies that had submitted new drug applications (NDAs) or biologics license applications (BLAs) to the FDA for new drug or biological products. The FDA issues a CRL when it is rejecting a NDA or BLA on the grounds that the product in question that fails to meet statutory or regulatory standards. The CRLs published were mostly issued between 2020 and 2024, however, all products ultimately received approval after the recipient companies corrected the cited deficiencies. Of the 200 letters, many were already publicly available in the FDA’s Drugs@FDA database.